Multiple System Atrophy Market to Witness Growth During the Forecast Period (2022-32), Estimates DelveInsight |Key Companies – H Lundbeck A/S, Theravance Biopharma, Brain Neurotherapy Bio, Inc., Ionis Pharmaceuticals, Inc., Alterity Therapeutics

DelveInsight’s “Multiple System Atrophy – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Multiple system atrophy (MSA), historical and forecasted epidemiology as well as the Multiple System Atrophy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Multiple System Atrophy Overview
Multiple system atrophy (MSA) is a rare condition of the nervous system that causes gradual damage to nerve cells in the brain. This affects balance, movement, and the autonomic nervous system, which controls several basic functions, such as breathing, digestion, and bladder control.

Multiple System Atrophy Epidemiological Insights

• The total diagnosed prevalent cases of MSA in the United States were around 15,000 cases in 2022.
• The United States contributed to the largest diagnosed prevalent population of Multiple System Atrophy, acquiring ~43% of the 7MM in 2022. Whereas EU4 and the UK, and Japan accounted for around 27% and 30% of the total population share, respectively, in 2022.
• Among the EU4 countries, Germany accounted for the largest number of Multiple System Atrophy cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
• In the 7MM, approximately 54% of the patient share is attributed to males, whereas the remaining 46% of females suffer from Multiple System Atrophy.
• A higher number of diagnosed cases were estimated in the 50–59 age group, suggesting that the prevalence of Multiple System Atrophy increases with age.

Multiple System Atrophy Treatment Market

Current therapeutic management is based on symptomatic treatment. To date, no curative treatment is available for MSA. Tremor, rigidity, bradykinesia, and postural instability are core features of MSA-P and are observed irrespective of subtype in nearly 90% of cases. A poor or unstained response to levodopa is common and among the core diagnostic features of MSA, helping differentiate MSA-P from PD. In one study, nearly a third of MSA-P patients benefit from levodopa therapy, but temporarily with a mean duration of 3.5 years. Levodopa remains the first-line therapy with a trial of up to 2 g total daily dose of levodopa (titrated from 100 mg to 300 mg 3–4 times daily) recommended for at least 3 months. A clinically significant improvement is a 30% decrease in the UMSARS. Levodopa may worsen OH or cause other more severe side effects less common among PD patients. Reports of deterioration with the medication withdrawal, even in the context of apparent nonresponse, are common and may justify the continuation of treatment.

Leading Companies Working in the Multiple System Atrophy Market

• H Lundbeck A/S
• Theravance Biopharma
• Brain Neurotherapy Bio, Inc.
• Ionis Pharmaceuticals, Inc.
• Alterity Therapeutics

And many others

Promising Therapies in the Multiple System Atrophy Market

• R0185
• Riboflavin
• IVMED-80
• PXL-330

And many others

Learn more about the key companies and emerging therapies @ Multiple System Atrophy Therapeutics Market Analysis

Scope of the Multiple System Atrophy  Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, Japan]

Key Multiple System Atrophy  Companies: H Lundbeck A/S, Theravance Biopharma, Brain Neurotherapy Bio, Inc., Ionis Pharmaceuticals, Inc., Alterity Therapeutics, and many others.

Key Multiple System Atrophy Pipeline Therapies: R0185, Riboflavin, IVMED-80, PXL-330, and many others.

Therapeutic Assessment: Multiple System Atrophy  current marketed and emerging therapies

Multiple System Atrophy Market Dynamics: Multiple System Atrophy market drivers and Barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

Unmet Needs, KOL’s views, Analyst’s views, Multiple System Atrophy Market Access, and Reimbursement

Table of Contents

1. Multiple System Atrophy Market Key Insights
2. Multiple System Atrophy Market Report Introduction
3. Multiple System Atrophy Market Overview at a Glance
4. Multiple System Atrophy Market Executive Summary
5. Disease Background and Overview
6. Multiple System Atrophy Treatment and Management
7. Multiple System Atrophy Epidemiology and Patient Population
8. Patient Journey
9. Multiple System Atrophy Emerging Drugs
10. 7MM Multiple System Atrophy Market Analysis
11. Multiple System Atrophy Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Multiple System Atrophy Market Drivers
15. Multiple System Atrophy Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Download the sample pages @ Multiple System Atrophy Market Outlook

Trending Reports

Cather Related Blood Stream InfectionsMarket

Schizophrenia

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Contact Us

Adya Kaul

info@delveinsight.com

www.delveinsight.com